Efficacy and safety of direct-acting antivirals in treatment of hepatitis C patients in Republic of Srpska: A real-life study
Abstract
The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection. This real-life multi-centric study was performed in Clinic for infectious diseases University clinical centre Republic of Srpska Banja Luka and it included a total of 89 patients. All patients received the adequate doses of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (RTV) + dasabuvir (DSV) plus ribavinin (RBV). RBV was given to all patients except to those with HCV sub-genotype 1b. DSV was not administered to patients infected with HCV genotype 4. For the majority of patient the treatment duration was 12 weeks. Ten patients with liver cirrhosis the duration of treatment was 24 weeks. Viraemia was assessed at four points in time: at baseline, four weeks after the beginning of treatment (rapid viral response, RVR), 12 or 24 weeks after the beginning of treatment (end of treatment response - ETR), and 12 weeks after the end of treatment (sustained viral response - SVR). Complete ETR after 12 weeks of treatment was achieved in 79 patients, while in 10 high-risk patients it was achieved after 24 weeks of treatment. Full SVR was recorded in 88 patients 12 weeks after the end of treatment. This therapy was well tolerated and mild adverse effects were recorded in only 10 patients. Treatment of patients with chronic HCV infection with OBV/PTV/RTV + DSV + RBV resulted in excellent antiviral activity and mild adverse events.
Key words: Hepatitis C virus; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Ribavirin
References
World Health Organization (WHO). Hepatitis C - factsheets. 2017. Available at: htpp://www.who.int/mediacentre/factsheets/fs164/en/, accessed on: Updated October 2017
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015¸61: 77-87.
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-44.
World Health Organization (WHO). Hepatitis C - factsheets. 2014. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/, accessed on: 15.01.2015.
Petrović J, Salkić NN, Ahmetagić S, Stojić V, Mott-Divković S. Prevalence of chronic hepatitis B and hepatitis C among first time blood donors in Northeast Bosnia and Herzegovina: en estimate of prevalence in general population. Hepat mon 2011; 11(8):629-33.
Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13:311-5.
European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
Lucejko M, Parfieniuk-Kowerda A, Flisiak R. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin Pharmacother 2016; 17:1153-64.
Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Wiercinska-Drapalo A, Zarebska-Michaluk D, Fleischer-Stepniewska K, et al. Efficacy and safety of Parytaprewir/r/Ombitaswir and Dazabuwir with or without Ribavirin in real life therapy of Polish patients with chronic hepatitis C – an interim analysis of AMBER study data. Clin Exp Hepatol 2015; 1(2):84.
Flisiak R, Janczewska E, Mawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016; 44:946-56.
Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol 2016;2:34-7.
Lawitz E, Makara M, Akarca US et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 2015; 149:971-80.
Alswat KA, Babatin MA, Abdelrahman AA, Al-Hamoudi WK, Alghamdi AS, Abdo A, Sanai FM. Treatment of chronic hepatitis C genotype 4-infected patients with ombitasvir /paritaprevir /ritonavir plus ribavirin: Real life data from Saudi Arabia. Hepatology 2016; 64(1 Suppl): 974A-975A.
Rodriguez-Osorio I, Cid P, Morano L, Castro A, Suarez M, Delgado M, et al. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol 2017;88:58-61.
McCombs J, Mc Ginnis J, Fox S, et al. Analysis of the real world effectiveness of direct acting antivirals treatments of hepatitis C in large population. J Hepatol 2016; 64(Suppl 2):LBP-510.
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016; 44:400-10.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).